ArticleBMC cardiovascular disorders2026
Sex-stratified polygenic risk scores for coronary artery disease incidence: Insights from a 20-year cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPolygenic risk scores (PRS) utilize genetic variants to evaluate susceptibility to diseases. While the performance of PRS has been extensively studied in European populations, its accuracy and validation in the Middle East, particularly in Iran, remain underexplored. We aimed to assess whether PRSs improve coronary artery disease (CAD) prediction beyond clinical risk factors using sex-stratified analyses.
methodsThis longitudinal study leveraged data from the Tehran cardiometabolic genetic study (TCGS) cohort (N = 16,226), a long-term population-based study in Iran, including participants free of baseline CAD. We evaluated three established CAD-PRSs (PRS241, PRS175, PRS161) derived from GWAS of European cohorts, alongside a meta-PRS and multi-ancestry data. Multivariable Cox proportional hazards regression models were employed to assess the association between each PRS and CAD incidence, adjusting for established clinical covariates. Sensitivity analyses were conducted by sequentially adjusting for clinical risk factors to evaluate the independent effect of the PRS. Incremental predictive value beyond clinical factors was evaluated using net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA).The association of clinical risk factors associated with PRS was also investigated.
resultsOver a median follow-up of 15 years in 4,594 individuals, 991 CAD events occured. PRS241 demonstrated consistent sex-stratified associations, with a 70% increased risk in females (HR = 1.70, 95% CI: 1.28-2.25) and 54% in males (HR = 1.54, 95% CI: 1.22-1.93) comparing highest versus lowest quartiles. In sensitivity analyses, adjustment for HDL, LDL, hypertension, and diabetes resulted in only modest attenuation of these associations, with PRS241 maintaining significant independent risk. PRS161 was significantly associated with CAD only in males (38% increased risk), while PRS175 showed no significant associations in either sex. Integrating PRS241 into clinical risk models yielded small improvements in CAD prediction, indicated by enhanced discrimination (female: ΔC = 0.004; male: ΔC = 0.004) and reclassification (males: relative IDI = 0.0255). DCA further confirmed small net benefit for PRS241. Also, PRS241 and PRS161 were linked to adverse HDL levels in both sexes (PRS161: β = - 0.0068, FDR P-value = 0.002 in females ; β = - 0.006, FDR P-value = 0.010 in males. PRS241: β = - 0.005, FDR P-value = 0.007 in females ; β = - 0.005, FDR P-value = 0.012 in males). Notably, PRS241 also showed sex-stratified associations with hypertension (OR = 1.11, FDR P-value = 0.04) and diabetes (OR = 1.66, FDR P-value = 0.008) exclusively in females.
conclusionThese findings demonstrate that incorporation of PRS241 into established clinical risk factors provides small but complementary value for CAD risk prediction. This may facilitate improved risk stratification and support more targeted primary prevention strategies in both sexes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.